{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:47:16Z","timestamp":1773074836305,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T00:00:00Z","timestamp":1536451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"abstract":"\n Tenofovir alafenamide (\n TAF<\/jats:styled-content>\n ) is indicated for adult patients with chronic hepatitis B virus (\n HBV<\/jats:styled-content>\n ) infection with compensated liver disease at an oral dose of 25\u00a0mg\/day.\n TAF<\/jats:styled-content>\n is a more stable prodrug in the plasma than tenofovir disoproxil fumarate (\n TDF<\/jats:styled-content>\n ), leading to decreased plasma exposure of tenofovir. Decreased exposure is thought to reduce the risk of long\u2010term\n TDF<\/jats:styled-content>\n toxicities, such as nephrotoxicity and decreased bone mineral density (BMD).\n TAF, a nucleotide reverse transcriptase inhibitor,<\/jats:styled-content>\n has the same mechanism of action as TDF. The results of phase\n III<\/jats:styled-content>\n primary trials and extensions showed that\n TAF<\/jats:styled-content>\n is noninferior to\n TDF<\/jats:styled-content>\n at suppressing the\n HBV<\/jats:styled-content>\n viral load in treatment\u2010naive and treatment\u2010experienced\n HB<\/jats:styled-content>\n eAg\u2010negative and\n HB<\/jats:styled-content>\n eAg\u2010positive patients at 48\u00a0weeks, 96\u00a0weeks, and 144\u00a0weeks of therapy. The most commonly reported adverse events were headache, abdominal pain, fatigue, cough, nausea, and back pain. At all evaluated time points (out to 144\u00a0wks of treatment), patients who received\n TAF<\/jats:styled-content>\n had less risk of nephrotoxicity and less of a decline in BMD than the patients who received\n TDF<\/jats:styled-content>\n .\n TAF<\/jats:styled-content>\n appears to be safe in patients with a creatinine clearance (Cl\n cr<\/jats:sub>\n ) above 15\u00a0ml\/min; however,\n TAF<\/jats:styled-content>\n is not currently recommended in patients with an estimated Cl\n cr<\/jats:sub>\n below this threshold.\n TAF<\/jats:styled-content>\n is safe in patients with mild hepatic impairment but is not currently recommended in patients with moderate or severe hepatic impairment (Child\u2010Pugh class B or C).\n <\/jats:p>","DOI":"10.1002\/phar.2174","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T07:48:45Z","timestamp":1534578525000},"page":"1051-1057","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-7979","authenticated-orcid":false,"given":"Lindsey M.","family":"Childs\u2010Kean","sequence":"first","affiliation":[{"name":"University of Florida College of Pharmacy Gainesville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric F.","family":"Egelund","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Jourjy","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy Orlando Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,9]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Centers for Disease Control and Prevention.Hepatitis B FAQ's for health professionals. Available fromhttps:\/\/www.cdc.gov\/hepatitis\/hbv\/hbvfaq.htm#overview. Accessed December 7 2017."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_5_1","unstructured":"Gilead Sciences Inc.Viread (tenofovir disoproxil fumarate) [product information].Foster City CA;2017."},{"key":"e_1_2_11_6_1","unstructured":"Gilead Sciences Inc.Vemlidy (tenofovir alafenamide) [product information].Foster City CA;2017."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01152-15"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000167155.44980.e8"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000168882.67942.3f"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt532"},{"key":"e_1_2_11_12_1","unstructured":"Center for Drug Evaluation and Research.Clinical pharmacology and biopharmaceutics review(s). Available fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208464Orig1s000ClinPharmR.pdf. Accessed June 14 2018."},{"issue":"1","key":"e_1_2_11_13_1","article-title":"No resistance to tenofovir alafenamide detected through 96\u00a0weeks of treatment in patients with chronic hepatitis B [abstract 26]","volume":"66","author":"Chan HL","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"issue":"1","key":"e_1_2_11_18_1","article-title":"Improved bone and renal safety at 1\u00a0year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 phase 3 studies in HBeAg\u2010positive and HBeAg\u2010negative patients with chronic hepatitis B (CHB) [abstract 904]","volume":"66","author":"Pan CQ","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_2_11_20_1","unstructured":"Food and Drug Administration.FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available fromhttps:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm. Accessed June 15 2018."},{"key":"e_1_2_11_21_1","unstructured":"Food and Drug Administration.Questions and Answers on FDA's Adverse Event Reporting System (FAERS). Available fromhttps:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Accessed June 15 2018."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00005-16"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001623"},{"key":"e_1_2_11_24_1","unstructured":"Clinicaltrials.gov.Efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)\u2010containing regimens in participants with chronic Hepatitis B virus (HBV) infection and stage 2 or greater chronic kidney disease how have received a liver transplant. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02862548?term=tenofovir+alafenamide&cond=Hepatitis+B&rank=9. Accessed June 14 2018."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit601"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508660"},{"key":"e_1_2_11_27_1","unstructured":"Clinicaltrials.gov.Tenofovir alafenamide (TAF) in children and adolescents with chronic Hepatitis B infection. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932150?term=tenofovir+alafenamide&cond=Hepatitis+B&age=0&rank=1. Accessed June 14 2018."},{"key":"e_1_2_11_28_1","unstructured":"Clinicaltrials.gov.Efficacy and safety of E\/C\/F\/TAF (Genvoya\u00ae) in HIV\u20101\/Hepatitis B co\u2010infected adults. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02071082?term=tenofovir+alafenamide&cond=Hepatitis+B&draw=2&rank=20§=Xa870156#outcome4. Accessed June 14 2018."},{"key":"e_1_2_11_29_1","unstructured":"Clinicaltrials.gov.Safety and efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine\/Tenofovir Disoproxil Fumarate in treatment na\u00efve HIV\u20101 and Hepatitis B co\u2010infected adults. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03547908?term=tenofovir+alafenamide&cond=Hepatitis+B&draw=2&rank=18. Accessed June 14 2018."},{"key":"e_1_2_11_30_1","unstructured":"Clinicaltrials.gov.TAF for HIV\u2010HBV with renal dysfunction. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03115736?term=tenofovir+alafenamide&cond=Hepatitis+B&draw=2&rank=19. Accessed June 14 2018."},{"key":"e_1_2_11_31_1","unstructured":"Clinicaltrials.gov.Elvitegravir\/cobicistat\/emtricitabine\/tenofovir\u00a0alafenamide as maintenance treatment for HIV\/HBV co\u2010infection. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425994?term=tenofovir+alafenamide&cond=Hepatitis+B&draw=2&rank=15. Accessed June 14 2018."},{"key":"e_1_2_11_32_1","unstructured":"GoodRx.com.Vemlidy. Available fromhttps:\/\/www.goodrx.com\/vemlidy. Accessed on April 15 2018."},{"key":"e_1_2_11_33_1","unstructured":"Gilead Sciences Inc.Vemlidy patient support. Available fromhttps:\/\/vemlidyhcp.com\/copay_patient_support\/. Accessed December 7 2017."},{"issue":"5","key":"e_1_2_11_34_1","first-page":"PIN 41","article-title":"Cost\u2010effectiveness analysis of first\u2010line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcriptase inhibitor (NRTI), for the management of chronic Hepatitis B (CHB) in the United States (US)","volume":"20","author":"Dusheiko G","year":"2017","journal-title":"Value Health"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:34:30Z","timestamp":1761068070000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,9]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/phar.2174"],"URL":"https:\/\/doi.org\/10.1002\/phar.2174","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,9]]},"assertion":[{"value":"2018-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}